Valuation: Dyne Therapeutics, Inc.

Market Cap 3.18B 2.85B 2.62B 2.38B 4.44B 302B 4.52B 31.26B 12.55B 159B 11.94B 11.69B 501B P/E 2026 *
-4.7x
P/E 2027 * -5.06x
Enterprise Value 2.41B 2.16B 1.99B 1.8B 3.37B 229B 3.43B 23.7B 9.52B 121B 9.05B 8.86B 380B EV / Sales 2026 *
-
EV / Sales 2027 * 51.2x
Free-Float
98.32%
Yield 2026 *
-
Yield 2027 * -
1 day-2.05%
1 week+5.83%
Current month+3.60%
1 month+2.96%
3 months-33.51%
6 months-4.14%
Current year-14.67%
1 week 15.53
Extreme 15.53
17.59
1 month 14.13
Extreme 14.13
17.59
Current year 14
Extreme 14
27.3
1 year 14
Extreme 14
27.3
3 years 6.36
Extreme 6.36
47.45
5 years 4.3
Extreme 4.3
47.45
10 years 4.3
Extreme 4.3
47.45
Manager TitleAgeSince
Chief Executive Officer 63 25/03/2024
Director of Finance/CFO 58 31/03/2025
Chief Tech/Sci/R&D Officer - 28/04/2025
Director TitleAgeSince
Director/Board Member 62 01/11/2018
Chairman 56 01/11/2018
Director/Board Member 51 01/11/2018
Date Insider Type Main position Quantity % Market Cap. Importance
02/10/26 Buy

Director

2,500 0.0015%
08/09/26 Sell

Executive/Senior Manager

-185 0.0001%
08/09/26 Sell

Chief Technology Officer

-1,290 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
-2.05%+5.83%-29.37%+152.11% 3.18B
-0.62%+0.50%+33.92%+60.07% 64.38B
+0.35%+3.04%+12.64%+83.62% 56.16B
+0.53%+2.55%+13.90%+104.77% 54.16B
-2.81%-3.95%+22.72%+48.57% 45.33B
-0.33%-3.12%+17.62%+117.27% 42.25B
+0.55%+1.93%+229.73%+928.00% 40.78B
+3.27%+47.40%+110.44%+94.92% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
Average -0.13%+5.05%+44.65%+162.94% 39.59B
Weighted average by Cap. -0.01%+3.68%+48.94%+162.39%

Financials

2026 *2027 *
Net sales - 53.4M 47.83M 43.99M 39.86M 74.51M 5.07B 75.9M 525M 211M 2.67B 200M 196M 8.41B
Net income -643M -576M -530M -480M -897M -61.07B -914M -6.32B -2.54B -32.12B -2.41B -2.36B -101B -658M -590M -542M -491M -919M -62.51B -936M -6.47B -2.6B -32.88B -2.47B -2.42B -104B
Net Debt -769M -689M -634M -574M -1.07B -73.06B -1.09B -7.56B -3.03B -38.43B -2.89B -2.83B -121B -449M -402M -370M -335M -626M -42.61B -638M -4.41B -1.77B -22.41B -1.68B -1.65B -70.68B
Projected Income Statement - Annual - Dyne Therapeutics, Inc.
Logo Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.
Employees
289
Date Price Change Volume
31/10/26 $16.69 -2.05% 1,449,801
29/10/26 $17.04 +0.35% 1,427,329
28/10/26 $16.98 +0.24% 2,178,108
27/10/26 $16.94 +7.76% 3,002,014
26/10/26 $15.72 +0.64% 1,741,943
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Dyne Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
17.04USD
Average target price
34.33USD
Spread / Average Target
+101.49%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Dyne Therapeutics, Inc.